Literature DB >> 18718742

Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis.

A J Brink1, G A Richards, R R Cummins, J Lambson.   

Abstract

The optimum teicoplanin loading dose and duration of therapy required for rapid attainment of a therapeutic trough plasma concentration (C(min)) (> or = 10mg/L for serious Gram-positive infections and > or = 20mg/L for deep-seated infections) are not known. In this open-label, multicentre, observational study, teicoplanin levels were determined following administration of loading doses of 6 mg/kg every 12h on Day 1 followed by 6 mg/kg once or twice daily to hospitalised patients with suspected or diagnosed Gram-positive infections. C(min) levels for the first 4 days of treatment were collected 15min prior to drug administration. Levels were determined with an Abbott TDx/FLx Analyzer and Seradyn Teicoplanin Innofluor Assay Kit. The two target trough values (> or = 10mg/L and > or = 20mg/L) were only achieved by Day 4 in the once-daily group (n=34; mean 9.55 mg/L, 95% confidence interval (CI) 8.17-10.94 mg/L) and in the twice-daily group (n=40; mean 21.8 mg/L, 95% CI 17.21-26.39 mg/L), respectively. However, the mean C(min) in the twice-daily group was > or = 10mg/L (11.03 mg/L) by Day 2. To achieve rapid therapeutic C(min) concentrations targeted for the majority of serious Gram-positive infections, we recommend teicoplanin loading doses of 6 mg/kg every 12h for 48h followed by once-daily for infections other than infective endocarditis, septic arthritis and osteomyelitis. Regarding the latter infections, higher loading doses might be warranted to reach rapid steady-state concentrations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18718742     DOI: 10.1016/j.ijantimicag.2008.05.012

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  16 in total

1.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

Review 2.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

Review 3.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

4.  Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.

Authors:  Takafumi Nakano; Yoshihiko Nakamura; Tohru Takata; Keiichi Irie; Kazunori Sano; Osamu Imakyure; Kenichi Mishima; Koujiro Futagami
Journal:  Int J Clin Pharm       Date:  2016-04-28

5.  Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.

Authors:  T Ueda; Y Takesue; K Nakajima; K Ichiki; A Doita; Y Wada; T Tsuchida; Y Takahashi; M Ishihara; H Ikeuchi; M Uchino; T Kimura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-09       Impact factor: 3.267

Review 6.  The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients.

Authors:  Marta Ulldemolins; Jason A Roberts; Jordi Rello; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2011-02       Impact factor: 6.447

Review 7.  Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.

Authors:  Shuli Svetitsky; Leonard Leibovici; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

8.  Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features.

Authors:  Masafumi Seki; Kaori Yabuno; Koji Miyawaki; Yoshihiro Miwa; Kazunori Tomono
Journal:  Clin Pharmacol       Date:  2012-11-27

Review 9.  Evidence-based guidelines for empirical therapy of neutropenic fever in Korea.

Authors:  Dong-Gun Lee; Sung-Han Kim; Soo Young Kim; Chung-Jong Kim; Wan Beom Park; Young Goo Song; Jung-Hyun Choi
Journal:  Korean J Intern Med       Date:  2011-06-01       Impact factor: 3.165

10.  Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Yuki Hanai; Yoshiko Takahashi; Takashi Niwa; Toshihiko Mayumi; Yukihiro Hamada; Toshimi Kimura; Kazuaki Matsumoto; Satoshi Fujii; Yoshio Takesue
Journal:  J Antimicrob Chemother       Date:  2022-03-31       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.